Article Text

Download PDFPDF
Commentary on ‘The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised clinical trial’
  1. Jonathan Schaffir
  1. Associate Professor, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, USA
  1. Correspondence to Dr Jonathan Schaffir, Department of Obstetrics and Gynecology, The Ohio State University, Wexner Medical Center, 493C McCampbell Hall, 1581 Dodd Drive, Columbus, OH 43210, USA; jonathan.schaffir{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Providing effective contraception is a key component of postpartum care. Making sure that a woman does not get pregnant again before she is ready is important for both maternal and infant health. Preventing a short interpregnancy interval ensures adequate time to bond and care for the infant, allows adequate time for maternal recovery, and prevents complications with future pregnancy, such as preterm birth and low birth weight.1

Depot medroxyprogesterone acetate (DMPA) has several characteristics that make it ideal for this purpose. It is highly effective, reasonably inexpensive, does not require special training for administration, and …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles